top of page

Search

Tackling in vivo screening complexity

uelling
Feb 11
1 min read

Updated: May 7

Nature Methods highlights CRISPR-StAR, the proprietary CRISPR-screening technology of ViVerita.

https://www.nature.com/articles/s41592-025-02605-6#:~:text=CRISPR-StAR%20enables%20gene%20function,lines%20with%20low%20engraftment%20rates

Recent Posts

ViVerita Therapeutics Announces Research Collaboration with Boehringer Ingelheim to Accelerate Discovery of Novel Cancer Targets

ViVerita Therapeutics Announces Research Collaboration with Boehringer Ingelheim to Accelerate Discovery of Novel Cancer Targets

CRISPR-StAR to transform in vivo functional genomic screening | Nature Reviews Cancer

CRISPR-StAR to transform in vivo functional genomic screening | Nature Reviews Cancer

ViVerita Therapeutics licenses CRISPR-StAR patent from IMBA

ViVerita Therapeutics licenses CRISPR-StAR patent from IMBA

Comments

bottom of page